Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair

Samsung Medical Center8,325 enrolled

Overview

This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.

Among these patients, any patients who were prescribed SAPT or DAPT at the date of discharge from the index hospitalization for standard EVAR were defined as being in the SAPT group (N=4,162) and the DAPT group (N=4,163), respectively.

Study Type

OBSERVATIONAL

Enrollment

8,325

Conditions

Abdominal Aortic Aneurysms (AAA)Endovascular Aneurysm Repair (EVAR)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients who underwent EVAR for AAA and were successfully discharged Exclusion Criteria: * Patients who had experienced a myocardial infarction * Patients who had experienced a stroke * Patients who had experienced percutaneous coronary intervention * Patients who had history of peripheral disease * Patients who had major bleeding event within 1 year of admission * Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin * Patients who did not prescribe any antiplatelet therapy

Outcomes

Primary Outcomes

Major adverse cardiac and cerebrovascular events (MACCE)

composite of all-cause death, myocardial infarction (MI), or ischemic stroke

Time frame: 1 year after EVAR

Major or clinically relevant non-major bleeding

Diagnostic codes in the primary or secondary position and transfusion receipt

Time frame: 1 year after EVAR

Re-intervention or surgery for AAAs

Time frame: 1 year after EVAR

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.